271 related articles for article (PubMed ID: 18951300)
1. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Hutas G
Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300
[TBL] [Abstract][Full Text] [Related]
2. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
3. [CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
[No Abstract] [Full Text] [Related]
4. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
5. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
6. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab: a step forward in the evolution of B-cell therapy.
Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
[TBL] [Abstract][Full Text] [Related]
8. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.
Rubbert-Roth A
Curr Opin Mol Ther; 2010 Feb; 12(1):115-23. PubMed ID: 20140823
[TBL] [Abstract][Full Text] [Related]
9. IDEC-131. IDEC/Eisai.
Dumont FJ
Curr Opin Investig Drugs; 2002 May; 3(5):725-34. PubMed ID: 12090546
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A; White AJ
Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
[TBL] [Abstract][Full Text] [Related]
11. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.
Tahir H; Rohrer J; Bhatia A; Wegener WA; Isenberg DA
Rheumatology (Oxford); 2005 Apr; 44(4):561-2. PubMed ID: 15644390
[No Abstract] [Full Text] [Related]
12. IDEC-114 (IDEC).
Schopf RE
Curr Opin Investig Drugs; 2001 May; 2(5):635-8. PubMed ID: 11569938
[TBL] [Abstract][Full Text] [Related]
13. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab. Elan/Biogen.
Elices MJ
Curr Opin Investig Drugs; 2003 Nov; 4(11):1354-62. PubMed ID: 14758775
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Crowley C; Boyman O
Front Immunol; 2021; 12():788830. PubMed ID: 35185862
[TBL] [Abstract][Full Text] [Related]
16. [CD20 antibody for treatment of rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2005 Jan; 63 Suppl 1():544-8. PubMed ID: 15799415
[No Abstract] [Full Text] [Related]
17. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic.
Silverman GJ
Arthritis Rheum; 2005 Feb; 52(2):371-7. PubMed ID: 15692969
[No Abstract] [Full Text] [Related]
18. Emerging biological therapies in systemic lupus erythematosus.
Mount GR; Gilliland WR
Clin Pharmacol Ther; 2008 Jan; 83(1):167-71. PubMed ID: 18000515
[TBL] [Abstract][Full Text] [Related]
19. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
Dimitrov A
Curr Opin Investig Drugs; 2007 Aug; 8(8):653-61. PubMed ID: 17668367
[TBL] [Abstract][Full Text] [Related]
20. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
